Brahim Gargouri Ph.D.,’s Post

🔬 A Breakthrough for the Future of Medicine: Philadelphia Business Journal John George went onsite to ThirdLaw Molecular's labs and dives into the science for the new magical molecules. What does this mean for patients? Temple University spinout ThirdLaw Molecular's 'lock and key' molecule looks to make drug creation faster and less expensive Article here: https://lnkd.in/eage7TUK Imagine a world where drug treatments are faster, more precise, and more affordable—where diseases once considered untreatable finally have solutions. ThirdLaw Molecular, led by Christian Schafmeister is making that future a reality with its groundbreaking Spiroligomer™ macromolecules. For patients, this innovation could mean: ✅ New hope for “undruggable” diseases – Spiroligomers can target proteins that small molecules and biologics cannot. ✅ Faster drug development – Bringing life-changing treatments to market quicker. ✅ More effective, personalized therapies – Reducing side effects and improving outcomes. ✅ Greater accessibility – A shift toward more scalable, cost-effective drug manufacturing. With $16M in DoD grants and a newly launched 4.5 billion-molecule DNA-encoded library, ThirdLaw is leading the charge toward a future where medicine is smarter, safer, and more tailored to each patient’s needs. This is more than just a scientific breakthrough—it’s a transformational moment for healthcare. 📖 Learn more: https://lnkd.in/exsrJbWR #FutureOfMedicine #PrecisionMedicine #DrugDiscovery #PatientImpact #ThirdLawMolecular #Spiroligomer #HealthcareInnovation

Great feature by the @philadelphia business journal on the incredible work by the ThirdLaw Molecular team, led by Dr. Christian Schafmeister. The company is pioneering Spiroligomer™ macromolecules—a breakthrough technology that has the potential to revolutionize drug discovery! 🚀 With the recent launch of a 4.5 billion-molecule DNA-encoded library, ThirdLaw is opening new doors for precision medicine, making drug development faster, more targeted, and cost-effective. This is a huge step forward for tackling previously undruggable disease targets! 🔬 Backed by $16M in DoD grants and a $1.5M seed round, this team is on an exciting trajectory to reshape the future of biotech and pharma innovation. Congratulations to the entire ThirdLaw Molecular team—your dedication and innovation are truly inspiring! Looking forward to seeing what’s next. 

The SEED Biosciences team had a great time exhibiting at Festival of Biologics last week! It was brilliant to be a part of Europe's largest biologics event and meet with new and established connections. 👋 The event highlighted that in B cell screening for antibody discovery, there is significant interest in using a gentle device that can handle the most precious and rare cells without loss. While FACS sorting effectively enriches target B cells, the low number of enriched cells can hinder individual isolation. DispenCell, capable of operating with as few as 100 cells, is an ideal solution for this process. We also found that surprisingly, many scientists are still unaware of automated seeding devices and continue using limiting dilution for this step despite the lack of reliability of the method. DispenCell-S4 delivers high-efficiency single cell seeding with reliable proof of clonality, surpassing FDA standards. Our new award-winning single large-particle dispenser Dispen3D was popular among visitors to our stand for drug screening applications. Dispen3D offers unprecedented accuracy and efficiency in cell culture techniques, enabling researchers to conduct high-precision experiments that drive advancements in drug discovery, personalized medicine, and regenerative therapies. To learn more, check out Georges Muller's #LiveWithChaudhrey interview from the event by following the link below! https://lnkd.in/gWM8bEEs #FestivalOfBiologics #CellLineDevelopment #TopClones #Monoclonality #FDA #GMP #DrugScreening #DrugDiscovery

🚨 We’re thrilled to announce the 4th Annual ALS Drug Development Summit, taking place May 12-14, 2025, in Boston! 🌟 This year’s summit couldn’t come at a more pivotal time for ALS and FTD drug development. With groundbreaking advancements like QurAlis and Eli Lilly’s ASO collaboration to restore UNC13A function, Trace Neuroscience’s $101M funding boost, and innovation in TDP43 biomarkers, the stage is set for transformative progress. Yet, challenges like regulatory hurdles and the removal of Relyvrio from the market remind us of the critical need to reimagine therapies that truly impact patients’ lives. Join 200+ leading experts and stakeholders—from discovery and biology to clinical and regulatory realms, spanning large pharma, biotech, academia, funding organizations, patients, and caregivers. Together, we’ll tackle the most pressing challenges and opportunities shaping ALS and FTD research and drug development. 📖 Access the full event guide and reserve your spot today: https://ter.li/b267d1 #ALSSummit2025 #DrugDevelopment #ALSResearch #FTDInnovation #Neuroscience #Biotech #Pharma #PatientCare #TDP43 #UNC13A 

🔔 Countdown Alert: Only 1 Week Until the Europe Xchanges Begin! 🔔 ⏳ Time is running out to join us at the Europe Xchanges! This is a unique chance to immerse yourself in breakthrough discussions with industry leaders, gain firsthand insights into cutting-edge advancements, and make valuable professional connections. 🌐 📅 Event Lineup: 🟡 Antibody Therapeutics Xchange - November 18 - https://lnkd.in/eupSzqSK 🟠 Oligonucleotide & Nucleic Acid Xchange - November 20 - https://lnkd.in/enGN4Qax 🔵 AI in Drug Discovery Xchange - November 21 - https://lnkd.in/esDycsXn Why Attend? ✨ Get Firsthand Knowledge – Join deep-dive roundtables with top experts in the field ✨ Network with Industry Leaders – Forge meaningful connections with key players in biopharma ✨ Boost Your Strategy – Gain actionable insights to supercharge your next R&D steps ✨ Explore Tomorrow’s Innovations – From antibody optimization to AI-driven breakthroughs With industry-focused tracks, exclusive sessions, and innovative content, these events are crafted to give you practical insights that can drive real change. 🚀 #EuropeXchange #AntibodyTherapeutics #OligonucleotideTherapeutics #NucleicAcidXchange #AIinDrugDiscovery #Biotech #Pharma #Networking #Innovation #DrugDevelopment #LifeSciences #Biopharma #Healthcare #Research #ClinicalTrials #Biotechnology #Therapeutics

🎯 Small Molecule Highlights: Biotech & Pharma News This Week🎯 This week, the world of #smallmolecules was buzzing with breakthroughs, business moves, and boundary-pushing science. Here’s the lowdown: 1️⃣ Jazz Pharmaceuticals' Big Win Jazz saw a stock boost after presenting data on their new small molecule #drug targeting #narcolepsy. The trial showed improved daytime alertness—welcome news for patients and investors alike! 2️⃣ Pfizer Bets Big on Molecular Glues Pfizer teamed up with TRIANA Biomedicines to explore molecular glue degraders, the latest trend in #protein degradation technology. This partnership showcases how small molecules are reshaping targeted therapies. 3️⃣ AstraZeneca Doubles Down The spotlight’s on #AZ as it ramps up development of its small molecule Dato-DXd, tackling challenging cancers with precision #chemistry. Early results hint at promising potential. 4️⃣ Alnylam Pharmaceuticals’s Ambitious FDA Filing Alnylam submitted a critical FDA application for its small molecule drug, positioning itself as a challenger to Pfizer in the heart-health space. Could we be looking at the next blockbuster? 5️⃣ Legal Battles & Triumphs Insulet Corporation pocketed $452M after winning a trade secrets lawsuit related to small molecule drug-device integration, underlining the industry’s high stakes. 💡 Why This Matters: Small molecules continue to be the backbone of drug discovery, with their versatility driving innovations across #cancer, #neurology, and #cardiovascular medicine. From partnerships to breakthroughs, this week proves that chemistry still rules the day! 💬What’s your take on the small molecule resurgence? Which of these trends excites you the most? #Biotech #Pharma #SmallMolecule #Innovation #Healthcare

As 2024 draws to a close, it’s great to reflect on the progress we’ve made at OMass. It’s been a year of growth, innovation and impactful progress, bringing us closer towards our mission of bringing transformative medicines to patients in need. The key highlights of OMass’ 2024 include: ·  The nomination of our first clinical candidate targeting the melanocortin-2 (MC2) receptor ·  Strengthening and expanding our team with the appointments of Dr. Steven Griffen as VP of Clinical Development, Angela Hecyk as Director of Clinical Operations, Stuart Hadley as Senior Director of CMC and Dr. Sarah Teichmann FMedSci FRS to our SAB, as well as the promotions of Dr. Hsin Loke to COO, Dr. Jon Roffey to SVP of Discovery and Non-Clinical and Professor Steven Charlton to CSO ·  Being named one of Fierce Biotech’s “Fierce 15” biotechnology companies for 2024 Looking ahead, we are poised for an exciting 2025. With our MC2 receptor antagonist set to enter IND-enabling studies, we continue to advance our immunology and rare disease portfolios, and our pipeline is stronger than ever. Our goal is clear: to build a fully integrated biopharma company that brings life changing medicines to market. Read the full blog here: https://lnkd.in/evdUGhye #festive #drugdiscovery #masspec #biotech #LifeScience #innovation

The University of Glasgow has joined forces with leading biotech company EVOTEC to develop an innovative drug aimed at improving heart disease treatment. Evotec will support work being undertaken by Professor Will Fuller and his team to co-develop small molecules targeting a well validated ion transporter implicated in cardiac arrhythmias. The backing is in the form of beLAB1407 Funding which was launched by Evotec and pharma company Bristol Myers Squibb to identify new disease-modifying therapeutic targets and platforms with the goal to develop these to new #spinout companies. The beLAB1407 award to Professor Fuller’s team represents the first for the University since the scheme – which bridges discovery science into investment-ready opportunities ready for preclinical development – was widened out last year to include more institutions. The team’s new findings offer the opportunity to address an age-old problem in securing selectivity which has hampered the development of safe and effective therapeutics drugs for this important class of targets. Using a combination of Evotec’s medicinal chemistry expertise coupled to the cardiovascular know-how of the Glasgow team, the project aims to deliver novel hits with proof of concept in a variety of models. Find out more via Glasgow City of Science and Innovation https://lnkd.in/eAV39dNq #UniversityOfGlasgow #Biotech #HeartDisease #DrugDevelopment #CardiacHealth #MedicinalChemistry #Therapeutics #InnovationInScience #Evotec #HealthcareResearch

Excited to kick off 2025 with a strong presence at key healthcare conferences in the U.S.! Join me and our Chairman, Mark Germain, as we connect with industry leaders to drive innovation in immunotherapeutics and biologics. Looking forward to collaborating with investors, pharma partners, and prospective clients. Let's make this year impactful! #VHH #MaxPlanck #Immunotherapy #Biologics #CDMO #Biotech #InvestmentOpportunities #HealthcareConferences #antibodies #Immunology #inflammation #psoriasis

𝐄𝐱𝐨𝐬𝐨𝐦𝐞 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐞𝐭 𝐭𝐨 𝐃𝐨𝐮𝐛𝐥𝐞 𝐛𝐲 2028! Download PDF Brochure: https://lnkd.in/gKjm7WUk The exosome research market is experiencing remarkable momentum, projected to reach $356M by 2028 from $169M in 2023 (16% CAGR). Here's why this matters: Driving forces: - Surging interest in exosome-based therapies - Growing prevalence of cancer and chronic diseases - Strong public & private funding support The future looks promising with emerging opportunities: ➡️ Rising investments in developing markets ➡️ Breakthrough potential in personalized medicine ➡️ Innovative therapeutic applications But challenges remain: - Need for standardized development protocols - Complex cargo loading mechanisms - Regulatory landscape navigation 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: Thermo Fisher Scientific, Bio-Techne, System Biosciences, QIAGEN, Lonza, NX Pharmagen (US), NanoSomiX (US), Miltenyi Biotec, Norgen Biotek, AMSBIO, Aethlon Medical, Inc., Anjarium Biosciences, Ciloa SAS, InnovaPrep LLC, Creative Medical Technologies Holdings, Inc. (US), ILIAS Biologics Inc., Unchained Labs, Rion, Cell Guidance Systems, INOVIQ Ltd (ASX:IIQ), Danaher Corporation, Exopharm Ltd, EVerZom, RoosterBio Inc., and Creative Biolabs Other Companies that are Operating in this Market Globally: University of Hawai'i Cancer Center  Allogene Therapeutics POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company     Human Longevity, Inc. IGM Biosciences, Inc. Rakuten Medical 2seventy bio MaxCyte, Inc. Adaptive Biotechnologies Corp. Menarini Stemline Roivant Sciences Nektar Therapeutics Arcus Biosciences Onyx Pharmaceuticals, Inc., an Amgen subsidiary   Century Therapeutics, Inc xilis BostonGene Agendia #BiotechInnovation #Healthcare #MedicalResearch #FutureOfMedicine #ExosomeTherapy #PersonalizedMedicine